PL1691805T3 - Zastosowanie kwasu urokanowego zdolnego do zakwaszania cytoplazmy komórkowej i do zapobiegania lub zatrzymywania proliferacji komórkowej - Google Patents

Zastosowanie kwasu urokanowego zdolnego do zakwaszania cytoplazmy komórkowej i do zapobiegania lub zatrzymywania proliferacji komórkowej

Info

Publication number
PL1691805T3
PL1691805T3 PL04798326T PL04798326T PL1691805T3 PL 1691805 T3 PL1691805 T3 PL 1691805T3 PL 04798326 T PL04798326 T PL 04798326T PL 04798326 T PL04798326 T PL 04798326T PL 1691805 T3 PL1691805 T3 PL 1691805T3
Authority
PL
Poland
Prior art keywords
person
acidify
urocanic acid
preventing
cell cytoplasm
Prior art date
Application number
PL04798326T
Other languages
English (en)
Inventor
Lasse Leino
Jarmo Laihia
Original Assignee
Biocis Pharma Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29763491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1691805(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocis Pharma Oy filed Critical Biocis Pharma Oy
Publication of PL1691805T3 publication Critical patent/PL1691805T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL04798326T 2003-12-09 2004-11-26 Zastosowanie kwasu urokanowego zdolnego do zakwaszania cytoplazmy komórkowej i do zapobiegania lub zatrzymywania proliferacji komórkowej PL1691805T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20031793A FI20031793A0 (fi) 2003-12-09 2003-12-09 Uusi anti-proliferatiivinen farmaseuttinen koostumus
EP04798326A EP1691805B1 (en) 2003-12-09 2004-11-26 The use of urocanic acid being able to acidify the cell cytoplasm and for preventing or halting cellular proliferation in a person
PCT/FI2004/000717 WO2005056007A1 (en) 2003-12-09 2004-11-26 The use of urocanic acid being able to acidify the cell cytoplasm and for preventing or halting cellular proliferation in a person

Publications (1)

Publication Number Publication Date
PL1691805T3 true PL1691805T3 (pl) 2008-11-28

Family

ID=29763491

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04798326T PL1691805T3 (pl) 2003-12-09 2004-11-26 Zastosowanie kwasu urokanowego zdolnego do zakwaszania cytoplazmy komórkowej i do zapobiegania lub zatrzymywania proliferacji komórkowej

Country Status (17)

Country Link
US (2) US20060189691A1 (pl)
EP (1) EP1691805B1 (pl)
JP (1) JP4825680B2 (pl)
CN (1) CN1889950B (pl)
AT (1) ATE396723T1 (pl)
AU (1) AU2004296570B2 (pl)
CA (1) CA2544720C (pl)
CY (1) CY1108163T1 (pl)
DE (1) DE602004014187D1 (pl)
DK (1) DK1691805T3 (pl)
ES (1) ES2303113T3 (pl)
FI (1) FI20031793A0 (pl)
PL (1) PL1691805T3 (pl)
PT (1) PT1691805E (pl)
SI (1) SI1691805T1 (pl)
WO (1) WO2005056007A1 (pl)
ZA (1) ZA200602940B (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20030379A0 (fi) * 2003-03-14 2003-03-14 Lasse Leino Uusi farmaseuttinen koostumus

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59106201D1 (de) * 1990-06-29 1995-09-14 Bode Chemie Gmbh & Co Dermatologische Zusammensetzungen mit einem Gehalt an cis-Urocaninsäure.
US5455036A (en) * 1990-06-29 1995-10-03 Bode Chemie Method of using cis-urocaninic acid for topically treating psoriasis
DE4122497C2 (de) 1991-07-02 1998-03-26 Wogepharm Gmbh Verwendung von trans-Urokaninsäure bei der prophylaktischen Therapie der Psoriasis
CA2114968A1 (en) * 1993-02-25 1994-08-26 John Wille Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
US5843979A (en) 1993-02-25 1998-12-01 Bristol-Myers Squibb Company Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
GB9306473D0 (en) * 1993-03-29 1993-05-19 Bioglan Lab Ltd Pharmaceutically useful compounds
US5686100A (en) * 1994-11-22 1997-11-11 E.R. Squibb & Sons, Inc. Prophylactic and therapeutic treatment of skin sensitization and irritation
US5576013A (en) * 1995-03-21 1996-11-19 Eastern Virginia Medical School Treating vascular and neoplastic tissues
WO1997047355A1 (en) * 1996-06-12 1997-12-18 Alza Corporation Reduction of skin sensitization in electrotransport drug delivery
DE19638064C2 (de) * 1996-09-18 1998-08-20 Voith Turbo Kg Verfahren zur Steuerung von Schaltvorgängen bei einem Fahrzeuggetriebe
DE19817295A1 (de) * 1998-04-18 1999-10-21 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an unsymmetrisch substituiertenTriazinderivaten zum Erhalt des Urocaninsäurestatus der Haut
US6420378B1 (en) * 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
AU2001257032A1 (en) * 2000-04-14 2001-10-30 University Of South Carolina Research Foundation Cloning, overexpression and therapeutic uses of bioactive histidine ammonia lyase
US6582734B1 (en) 2000-07-20 2003-06-24 Ecolab Inc. Antimicrobial composition useful for the treatment of bovine mastitis
US6541509B2 (en) * 2000-09-15 2003-04-01 Albert Einstein College Of Medicine Of Yeshiva University Method for treating neoplasia using combination chemotherapy
FI20030379A0 (fi) * 2003-03-14 2003-03-14 Lasse Leino Uusi farmaseuttinen koostumus

Also Published As

Publication number Publication date
AU2004296570B2 (en) 2011-01-06
US20060189692A1 (en) 2006-08-24
CN1889950A (zh) 2007-01-03
WO2005056007A1 (en) 2005-06-23
ATE396723T1 (de) 2008-06-15
CA2544720C (en) 2012-01-03
US8338475B2 (en) 2012-12-25
CA2544720A1 (en) 2005-06-23
EP1691805A1 (en) 2006-08-23
EP1691805B1 (en) 2008-05-28
ZA200602940B (en) 2007-07-25
JP2007513927A (ja) 2007-05-31
FI20031793A0 (fi) 2003-12-09
DE602004014187D1 (de) 2008-07-10
ES2303113T3 (es) 2008-08-01
SI1691805T1 (sl) 2008-08-31
CN1889950B (zh) 2011-02-09
DK1691805T3 (da) 2008-10-06
PT1691805E (pt) 2008-06-12
JP4825680B2 (ja) 2011-11-30
AU2004296570A1 (en) 2005-06-23
US20060189691A1 (en) 2006-08-24
CY1108163T1 (el) 2014-02-12

Similar Documents

Publication Publication Date Title
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
IS4146A (is) Lyfjablanda til að gefa dýrum um munn sem inniheldur prótonupumpublokkara
UA81638C2 (ru) Композиция метронидазола для местного применения для лечения заболеваний аноректального и перианального участков
BG106095A (bg) Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици
SE9900961D0 (sv) Novel compounds
AU2003247616A1 (en) Use of topical pharmaceutical compositions comprising an active agent and permeation-enhancing base for the manufacture of a medicament to treat various forms of inflammatory dermatosis
IT1252868B (it) Composizione farmaceutica anticefalalgica per somministrazione endonasale, procedimento per prepararla e suo impiego terapeutico
MY119403A (en) Novel compounds with analgesic effect.
GB9905425D0 (en) Pharmaceutical composition
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
PL374443A1 (pl) Nowe pochodne pirymidynoamidów oraz ich zastosowanie
NZ513096A (en) Compositions for treating inflammatory response
SE9802208D0 (sv) Novel compounds
PT1492773E (pt) Compostos de 4-(heterociclilo)-benzenossulfoximinapara o tratamento da inflamação
IL132853A (en) Composition for modulating the human sexual response
TW200606164A (en) New compounds
AU2173101A (en) Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents
SE9802209D0 (sv) Novel compounds
TW200503709A (en) Itching treating agent containing piperidine derivative as active ingredient
SI1691805T1 (sl) Uporaba urokanske kisline za nakisanje celične citoplazme in za preprečevanje ali zaustavitev celične proliferacije pri osebi
BE2016C017I2 (pl)
CY1107346T1 (el) Φαρμακευτικη συνθεση για την ενδοκυτταρια οξινιση με cis-ουροκανικο οξυ
BR0011880A (pt) Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêutica
AU2003294834A1 (en) Anthranilic acid amide derivatives and their pharmaceutical use
DE60312215D1 (de) Pharmazeutische zusammensetzung enthaltend einen ltb4-hemmer sowie einen cox-2-hemmer oder einen kombinierten cox1/2-hemmer